A new Covid variant, designated BA.3.2 and colloquially termed the Cicada variant, is rapidly spreading across the United States, raising concerns about its potential ability to evade protection from current vaccines. This development underscores the ongoing challenges in managing the pandemic as the virus continues to mutate.
Symptoms and Spread of the Cicada Variant
The symptoms associated with the Cicada variant mirror those of other Covid infections, including a runny or stuffy nose, fever, headache, fatigue, sneezing, a sore or "razor blade" throat, cough, muscle pain or body aches, vomiting, diarrhea, and changes to the sense of smell or taste. First detected in South Africa in 2024 and subsequently in the United States in June 2025, the variant has now been identified in clinical samples, traveller swabs, and wastewater across over 20 states, with reports indicating it has spread to 25 states in total.
Vaccine Efficacy and Scientific Concerns
Researchers have highlighted significant concerns regarding vaccine efficacy against BA.3.2. Studies show that the 2025–2026 LP.8.1-adapted mRNA Covid-19 vaccine demonstrated the lowest antibody neutralisation against this variant compared to other circulating strains. While BA.3.2 is not yet the dominant variant and detected cases have not shown increased severity, scientists stress the critical importance of continuous monitoring and adapting public health responses. They warn that the virus's ability to mutate necessitates proactive measures to prevent potential surges in infections.
Health authorities are urging vigilance, emphasizing that individuals should remain aware of symptoms and consider booster shots if recommended. The spread of the Cicada variant serves as a reminder of the unpredictable nature of the pandemic and the need for ongoing research and preparedness to combat emerging threats effectively.
